Coep

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents th...

38.56M Revenue (ttm) n/a Net Income (ttm) -26.26M Shares Out 21.54M EPS (ttm) -2.51 PE Ratio n/a Forward PE n/a Dividend n/a Ex-Dividend Date n/a Volume 228,441 Open 1.73 Previous Close 1.75 Day's Range 1.67 - 1.85 52-Week Range 1.03 - 21.42 Beta -0.57 Analysts Strong Buy Price Target 7.00 (+291.06%) Earnings Date Aug 8, 2023 About COEP Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclon...

• 100% Tuition Fee waiver for SC/ ST/ VJNT/ SBC/ OBC category students. • 100% Other Fees waiver for SC/ ST/ VJNT/ SBC/ OBC category students. • 100% Development Fee waiver for SC/ST category students. • Note: EBC/ OBC/ VJNT/ SBC candidates whose family income is above 8 lakhs are required to pay Open category Fees. Branch Placed (%) Civil Engineering 29.69% Computer Engineering 95.12% Electrical Engineering 73.91% Electronics and Telecommunication Engineering 72.60% Information Technology 97.50% Instrumentation and Control Engineering 83.87% Mechanical Engineering 68.50% Metallurgical Engineering 64.91% Production Engineering (Sandwich) 53.73% Planning 18.60% Overall (UG) 68.25% Branch Placed (%) Civil Engineering 47.76% Computer Engineering 97.22% Electrical Engineering 73.53% Electronics and Telecommunication Engineering 86.30% Information Technology 93.65% Instrumentation and Control Engineering 85.71% Mechanical Engineering 80.82% Metallurgical Engineering 64.81% Production Engineering (Sandwich) 77.97% Planning 33.33% Overall (UG) 76.14% Branch Placed (%) Civil Engineering 71.21% Computer Engineering 98.73% Electrical Engineering 88.16% Electronics and Telecommunication Engineering 91.55% Information Technology 96.92% Instrumentation and Control Engineering 97.44% Mechanical Engineering 75.00% Metallurgical Engineering 61.40% Production Engineering (Sandwich) 69.01% Planning 39.13% Total 79.53% Company Location 3DPLM Software Pune Accil Mumbai Accolite Mumbai ACG Wor...

Round Branch Cutoff Rank 4-Year B.E./B.Tech. Course 1 Civil Engineering -- 1 Computer Engineering -- 1 Electrical Engineering -- 1 Electronics and Telecommunication Engineering -- 1 Instrumentation and Control Engineering -- 1 Manufacturing Science and Engineering -- 1 Mechanical Engineering -- 1 Metallurgy and Material Technology -- Round Branch Cutoff Rank 4-Year B.E./B.Tech. Course 2 Civil Engineering -- 2 Computer Engineering -- 2 Electrical Engineering -- 2 Electronics and Telecommunication Engineering -- 2 Instrumentation and Control Engineering -- 2 Manufacturing Science and Engineering -- 2 Mechanical Engineering -- 2 Metallurgy and Material Technology -- Round Branch Cutoff Rank 4-Year B.E./B.Tech. Course 1 Civil Engineering 2757 1 Computer Engineering 126 1 Electrical Engineering 908 1 Electronics and Telecommunication Engineering 430 1 Instrumentation and Control Engineering 1447 1 Manufacturing Science and Engineering 3336 1 Mechanical Engineering 1413 1 Metallurgy and Material Technology 4548 Round Branch Cutoff Rank 4-Year B.E./B.Tech. Course 2 Civil Engineering 3658 2 Computer Engineering 296 2 Electrical Engineering 1296 2 Electronics and Telecommunication Engineering 610 2 Instrumentation and Control Engineering 1681 2 Manufacturing Science and Engineering 4205 2 Mechanical Engineering 1792 2 Metallurgy and Material Technology 5660 Round Branch Cutoff Rank 4-Year B.E./B.Tech. Course 1 Civil Engineering 9964 1 Computer Engineering 1925 1 Electrical Engineer...

WEXFORD, Pa., June 14, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 2,150,000 shares of common stock, (ii) 1,350,000 pre-funded warrants, (iii) 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and (iv) 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date. The warrants issued in this offering are fixed priced and do not contain any variable pricing, resets or priced based anti-dilution features. The pre-funded warrant is exercisable at $0.0001. The closing of the offering is expected to take place on or about June 16, 2023, subject to the satisfaction or waiver of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with this offering. The securities are being offered pursuant to a registration statement on Form S-1 (File No. 333-269782), which was declared effective by the United States Securities and Exchange Commission ("SEC") on June 13, 2023, and related MEF ...

• Research Tools • My MarketBeat • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Financial Calendars • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Market Data • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Stock Lists • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Headlines • • Mullen Automotive’s Dilution is Desperation • • Verizon is Paying You 7% to Own its Stock • • 3 Stock Trades to Make in June: Tesla, GitLab, Gevo • • Stocks Upgraded After Earnings and are Moving Higher • • • • • • • • • • • • • • • • • • • • • • • • • • • About • 3.5 Analyst's Opinion • Coeptis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. • According to analysts' consensus price target of $5.00, Coeptis Therapeutics has a forecasted upside of 179.3% from its current price of $1.79. • Coeptis Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest • Percentage of Shares Shorted2.65% of the float of Coeptis Therapeutics has been sold short. • Short Interest Ratio / Days to CoverCoepti...